Triple-negative breast cancer and obesity in a rural appalachian population

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 12, 2008, Pages 3319-3324

  Vona Davis, Linda ^a,b   Rose, David P ^a   Hazard, Hannah ^a,b   Howard McNatt, Marissa ^a,b   Adkins, Farrell ^a   Partin, Jessica ^a   Hobbs, Gerald ^b  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER SIZE; CAUCASIAN; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OBESITY; PRIORITY JOURNAL; PROGNOSIS; RURAL POPULATION; UNITED STATES;

ADULT; AGED; APPALACHIAN REGION; BODY MASS INDEX; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; OBESITY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; RURAL POPULATION; WEST VIRGINIA;

EID: 57449087033     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0544     Document Type: Article

References (46)

1. Ogawa Y, Moriya T, Kato Y, et al. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer 2004;11:267-75.
2. Gorlich M, Jandrig B. Steroid hormone receptors related to parameters characterizing the biology of human breast cancer. Tumori 1997;83:930-7.
3. Fisher ER, Redmond CK, Liu H, Rockette H, Fisher B. Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer. Cancer 1980;45:349-53.
4. Mauri FA, Maisonneuve P, Caffo O, et al. Prognostic value of estrogen receptor status can be improved by combined evaluation of p53, Bcl2 and PgR expression: an immunohistochemical study on breast carcinoma with long-term follow-up. Int J Oncol 1999;15:1137-47.
5. Nomura Y, Tashiro H, Hamada Y, Shigematsu T. Relationship between estrogen receptors and risk factors of breast cancer in Japanese pre- and postmenopausal patients. Breast Cancer Res Treat 1984;4:37-43.
6. Bentzon N, During M, Rasmussen BB, Mouridsen H, Kroman N. Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer 2008;122:1089-94.
7. Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS. Progesterone receptors as a prognostic factor in stage II breast cancer. N Engl J Med 1983;309:1343-7.
8. Ghafoor A, Jemal A, Ward E, Cokkinides V, Smith R, Thun M. Trends in breast cancer by race and ethnicity. CA Cancer J Clin 2003;53:342-55.
9. Rose DP, Royak-Schaler R. Tumor biology and prognosis in Black breast cancer patients: a review. Cancer Detect Prev 2001;25:16-31.
10. Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among White, Hispanic, and Black women in the United States. J Natl Cancer Inst 1994;86:705-12.
11. Chen VW, Correa P, Kurman RJ, et al. Histological characteristics of breast carcinoma in Blacks and Whites. Cancer Epidemiol Biomarkers Prev 1994;3:127-35.
12. Porter PL, Lund MJ, Lin MG, et al. Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer 2004;100:2533-42.
13. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007;110:876-84.
14. Bassett MT, Krieger N. Social class and Black-White differences in breast cancer survival. Am J Public Health 1986;76:1400-3.
15. Franzini L, Williams AF, Franklin J, Singletary SE, Theriault RL. Effects of race and socioeconomic status on survival of 1,332 Black, Hispanic, and White women with breast cancer. Ann Surg Oncol 1997;4:111-8.
16. Gordon NH. Socioeconomic factors and breast cancer in Black and White Americans. Cancer Metastasis Rev 2003;22:55-65.
17. Cui Y, Whiteman MK, Langenberg P, et al. Can obesity explain the racial difference in stage of breast cancer at diagnosis between Black and White women? J Womens Health Gend Based Med 2002;11:527-36.
18. Stephenson GD, Rose DP. Breast cancer and obesity: an update. Nutr Cancer 2003;45:1-16.
19. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
20. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the socalled triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007;109:1721-8.
21. Ihemelandu CU, Leffall LD, Jr., Dewitty RL, et al. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res 2007;143:109-18.
22. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34.
23. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24:5652-7.
24. Proctor BD, Dalaker J. US Census Bureau. Poverty in the United States: 2002. Washington (DC): U.S. Government Printing Office; 2003.
25. Ahluwalia IB, Mack KA, Murphy W, Mokdad AH, Bales VS. State-specific prevalence of selected chronic disease-related characteristics - Behavioral Risk Factor Surveillance System, 2001. MMWR Surveill Summ 2003;52:1-80.
26. American Cancer Society. Cancer facts and figures. American Cancer Society; 2005.
27. Simon MS, Severson RK. Racial differences in breast cancer survival: the interaction of socioeconomic status and tumor biology. Am J Obstet Gynecol 1997;176:S233-9.
28. Bowen RL, Duffy SW, Ryan DA, Hart IR, Jones JL. Early onset of breast cancer in a group of British Black women. Br J Cancer 2008;98:277-81.
29. Sastre-Garau X, Jouve M, Asselain B, et al. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 1996;77:113-20.
30. Li CI, Moe RE, Daling JR. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med 2003;163:2149-53.
31. Helin HJ, Helle MJ, Kallioniemi OP, Isola JJ. Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and DNA flow cytometry. Cancer 1989;63:1761-7.
32. Coradini D, Pellizzaro C, Veneroni S, Ventura L, Daidone MG. Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. Br J Cancer 2002;87:1105-11.
33. Drewnowski A, Specter SE. Poverty and obesity: the role of energy density and energy costs. Am J Clin Nutr 2004;79:6-16.
34. WV Health Statistics Center. West Virginia behavioral risk factor survey report, 2004-2005. WV Health Statistics Center: Charleston; 2007.
35. Lund MJ, Butler EN, Bumpers HL, et al. High prevalence of triple-negative tumors in an urban cancer center. Cancer 2008;113:608-15.
36. 1) breast carcinomas belonging exclusively to the ductal infiltrating variety. Cancer Genomics Proteomics 2007;4:399-402.
37. Van Calster B, Vanden B, I, Drijkoningen M, et al. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. Breast Cancer Res Treat 2008.
38. Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer 2001;92:720-9.
39. Maehle BO, Tretli S, Skjaerven R, Thorsen T. Premorbid body weight and its relations to primary tumour diameter in breast cancer patients; its dependence on estrogen and progesterone receptor status. Breast Cancer Res Treat 2001;68:159-69.
40. Porter GA, Inglis KM, Wood LA, Veugelers PJ. Effect of obesity on presentation of breast cancer. Ann Surg Oncol 2006;13:327-32.
41. Daniell HW, Tam E, Filice A. Larger axillary metastases in obese women and smokers with breast cancer - an influence by host factors on early tumor behavior. Breast Cancer Res Treat 1993;25:193-201.
42. Loi S, Milne RL, Friedlander ML, et al. Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1686-91.
43. Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 2007;14:189-206.
44. Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 2004;10:4325-31.
45. Liu CL, Chang YC, Cheng SP, et al. The roles of serum leptin concentration and polymorphism in leptin receptor gene at codon 109 in breast cancer. Oncology 2007;72:75-81.
46. Rakha EA, El Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32.